Enlivex Therapeutics Ltd. (ENLV) Earnings History
Profitable14 years of earnings data (2012–2025) · Positive TTM net income
Loading earnings history...
Enlivex Therapeutics Ltd. (ENLV) Earnings Overview
As of June 30, 2026, Enlivex Therapeutics Ltd. (ENLV) reported trailing twelve-month net income of $1.24B, reflecting +3590.4% year-over-year growth. The company earned $25.63 per diluted share over the past four quarters.
Looking at the long-term picture, ENLV's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.24B in fiscal 2025, representing a new all-time high.
Enlivex Therapeutics Ltd. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), MCRB (-$47M net income, 721.9% margin), ADMA ($165M net income, 28.8% margin), ENLV has comparable earnings metrics. Compare ENLV vs FATE →
ENLV Earnings vs Peers
Earnings metrics vs comparable public companies
ENLV Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.24B | +8329.2% | -$15M | $25.48 | - | - |
| 2024 | -$15M | +48.3% | -$16M | $-0.73 | - | - |
| 2023 | -$29M | +6.4% | -$29M | $-1.56 | - | - |
| 2022 | -$31M | -114.7% | -$26M | $-2.31 | - | - |
| 2021 | -$14M | -22.4% | -$19M | $-0.54 | - | - |
| 2020 | -$12M | -26.0% | -$10M | $-1.05 | -519.3% | -429.7% |
| 2019 | -$9M | -91.5% | -$9M | $-1.17 | - | - |
| 2018 | -$5M | +17.6% | -$5M | $-10.63 | - | - |
| 2017 | -$6M | +62.9% | -$6M | $-13.88 | - | - |
| 2016 | -$16M | -4.3% | -$16M | $-40.29 | - | - |
| 2015 | -$15M | -118.8% | -$15M | $-43.19 | - | - |
| 2014 | -$7M | -513.3% | -$7M | $-22.91 | - | - |
| 2013 | -$1M | -400.0% | -$1M | $-4.21 | - | - |
| 2012 | $-229,000 | - | $-226,000 | $-0.01 | - | - |
Download Data
Export ENLV earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ENLV — Frequently Asked Questions
Quick answers to the most common questions about buying ENLV stock.
What is ENLV earnings per share (EPS)?
ENLV trailing twelve-month (TTM) diluted EPS is $25.63, reflecting +3590.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Enlivex Therapeutics Ltd.'s net income?
Enlivex Therapeutics Ltd. (ENLV) trailing twelve-month net income is $1.2B as of 2025. Earnings grew +3590.4% year-over-year.
Is ENLV profitable?
Yes, ENLV is profitable with a TTM net income of $1.2B and a net profit margin of N/A.
What is ENLV's earnings growth rate?
ENLV compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are ENLV's profit margins?
Enlivex Therapeutics Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is +126.2%.
Is ENLV growing earnings?
Yes, ENLV earnings are accelerating — EPS growth of +3590.4% exceeds the 5-year CAGR of N/A. TTM net income reached $1.2B. Earnings momentum is strengthening.
What was ENLV's best earnings year?
Enlivex Therapeutics Ltd.'s highest annual net income on record is $1.2B, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were ENLV's earnings last quarter?
ENLV's most recent reported quarter was Q4 2025. Net income was $1.2B with diluted EPS of $25.79. For a full breakdown of all quarters, see the quarterly earnings table on this page.